Novavax Medical Information
DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN United Kingdom - Northern Ireland ONLY.
If you are NOT a Healthcare Professional in United Kingdom - Northern Ireland, please switch to the Consumer Medical Information page.
If you are a Healthcare Professional in another country, please go back to country selection.
Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)
This medicinal product has been given conditional marketing authorisation in Northern Ireland by the European Medicines Agency (EMA). NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
If you have any questions or concerns regarding the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted), please speak to your doctor, nurse or Healthcare Professional.
Important information
Summary of Product Characteristics (SmPC)
Package Leaflet (PL)
Request Medical Information
Do you have a medical or scientific question about a Novavax medicinal product? Get in touch with Novavax Medical Information experts who will provide tailored, evidence-based, balanced, and up-to-date medical information.
Healthcare Professionals may request medical information via ONE of the following ways:
Option 1: Complete and submit a Medical Information Request Form by clicking on the button below.
Option 2: Call +44 203 514 1838 between 09:00 - 17:00.
Report an Adverse Event (AE)
If you are concerned about an adverse event, it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card on the Google Play or Apple Store. When reporting, please include the vaccine brand and batch/Lot number if available.
Alternatively, adverse events of concern in association with NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted), can be reported to Novavax Pharmacovigillance at +44 203 514 1838 or via the Novavax Adverse Event Reporting Form.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Novavax and MHRA (in anonymised form) and dual reporting will create unnecessary duplicates.
Report a Product Quality Complaint
If you have a product quality complaint related to a physical issue with a Novavax product or its packaging, please report the complaint via ONE of the following ways:
Option 1: Complete and submit a Product Quality Complaint Form by clicking on the button below.
Report a Product Quality Complaint
Option 2: Call +44 203 514 1838 between 09:00 - 17:00.